Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial

ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most advanced clinical trial of single-agent carfilzomib demonstrating anti-cancer activity and progression-free survival in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

Data from the Phase 2 clinical trial of relapsed and refractory multiple myeloma patients were presented today in an oral session by Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York, at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO). In addition, Proteolix presented positive data today from an ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients and from a Phase 1b clinical trial of carfilzomib in combination with lenalidomide and dexamethasone during the "Lymphoma and Plasma Cell Disorders" poster session.

"In spite of advances in the treatment of multiple myeloma, new selective agents are needed for patients who have failed other available therapies," said Dr. Jagannath. "Carfilzomib is well tolerated and demonstrates clear single-agent activity in a heavily pre-treated multiple myeloma patient population. Patients enrolled in this Phase 2 trial lack treatment alternatives, having failed prior treatment with all approved agents and stem cell transplant."

Sustained Clinical Benefit in Relapsed and Refractory Patients

The Phase 2 clinical trial
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
(Date:5/23/2013)... 2013  Texas, premier physician associations today announced the ... tools they need to provide demonstrably better and more ... marketplace. "I am confident the Physician Services ... Stephen L. Brotherton , MD, president ... doctors are determined to make health care ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
(Date:5/25/2013)... York (PRWEB) May 25, 2013 ... litigation underway in U.S. District Court, Western District of ... According to a Case Management Order issued on ... the filing of contested motions in the Actos bladder ... motions. (In re: Actos Product Liability Litigation, MDL No. ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market (2012 – ... Materials, Packaging, & Geography: Trends & Forecasts” defines ... analysis and forecasting of the global revenue for ... restraining factors for the global food encapsulation markets ... market is segmented and revenue are forecasted on ...
(Date:5/25/2013)... 25, 2013 Providing patients with their best ... team of weight management professionals. But, aside from educating patients ... Diet Doc’s hCG diets also provide patients, who ... childhood like bullying, more control over their lives by achieving ... with the underlying factors of weight gain derived from earlier ...
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... patients who allegedly suffered serious, life-threatening episodes of internal bleeding ... federal litigation underway in U.S. District Court, Southern District of ... on the Court’s website, 818 Pradaxa side effect claims had ... 24, 2013. That’s up from 705 claims reported by ...
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 ... organization dedicated to brain cancer research and advocacy, comments ... for Extraterrestrial Physics, that shows incorporating cold atmospheric plasma ... glioblastoma cells. , According to a Science ... for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... to new therapeutic targets , , TUESDAY, June 24 (HealthDay ... factor in the development of B-cell lymphomas, one of ... with mice, researchers at the National Jewish Medical and ... the surface of B-cells can cooperate with the MYC ...
... 24 Behavioral Risk Management is an,important best ... message from,a survey conducted by the Disability Management ... in Behavioral Risk,Management., Additionally, survey results show ... emerging focus area to one that is showing ...
... programs due Aug. 7, WASHINGTON, June ... group for creation of accreditation standards and ... requests for quality standards,and measures for both ... 50 advisory committee members include employers, health ...
... leading brand of vitamin, mineral and dietary supplements hits, record milestone; ... ... health, ADA, Mich., June 24 NUTRILITE, the world,s leading,brand ... sales over the last 12 months as Amway/Quixtar,s message of,optimal health ...
... LONDON, June 24 NHS Choices ( http://www.nhs.uk ... a Live well guide on women,s,health aged 18-39 ... maintaining a,healthy lifestyle., Based on NHS accredited ... provides users with information about,walking to get healthy, ...
... Region of the American Red Cross is facing alarmingly ... of local hospitals. The,morning began with five of the ... zero O-, the universal blood type. In order,to meet ... Region should,maintain a minimum three-day supply of all eight ...
Cached Medicine News:Health News:Research Uncovers Clues to Lymphoma 2Health News:Behavioral Risk in the Workplace: Behavioral Risk Management Continues to be an Important Best Practice Area for Employers 2Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 2Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 3Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 4Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 5Health News:NUTRILITE(TM) Passes $3 Billion Mark in Annual Sales 2Health News:NUTRILITE(TM) Passes $3 Billion Mark in Annual Sales 3
... Agility is positioned to support ... to reduce medication and other ... workflow for pharmacy support staff ... blood products, lab specimens and ...
... Context-sensitive medicine is the ability of medical ... pre-determined ways based on what is happening ... associations a Radianse indoor positioning solution (IPS) ... it requires identity, location and time to ...
... VerdaSee Intelli-Storeroom™ was developed to create physically ... entrances and exits are converted to RFID ... RFID readers and antennas by VerdaSee's Field ... affixed to assets that are to be ...
... ability to track the movement of ... assets can be done. VerdaSee's "intellishelvess" ... Continuous cycle counting is possible with ... (RFID) technology makes this possible. VerdaSee ...
Medicine Products: